HomeBusinessCDSCO grants marketing approval for Sanofi's RSV antibody in India

CDSCO grants marketing approval for Sanofi’s RSV antibody in India

Mumbai, Aug 1 (IANS) The Central Drugs Standard Control Organisation (CDSCO) has granted marketing authorisation approval to Sanofi for Beyfortus, used for the prevention of respiratory syncytial virus (RSV), in India, the drug major said on Thursday.

RSV is a highly contagious virus that can lead to serious respiratory illness in infants and is also the leading cause of hospitalisation in infants worldwide.

“Beyfortus contains the monoclonal antibody nirsevimab in a prefilled injection used for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season,” Sanofi said.

The monoclonal antibody can also be administered in children up to 24 months of age.

“Prevention of RSV in India is still an unmet medical need. This makes the approval of Beyfortus a landmark moment for Sanofi in India,” said Preeti Futnani, General Manager – Sanofi Vaccines (India).

She noted the company is striving “to make Beyfortus available for all Indian parents to help protect their babies” against RSV.

Sanofi, in March 2017, announced an agreement with AstraZeneca to develop and commercialise Beyfortus.

As per the agreement, AstraZeneca will lead development and manufacturing activities, while Sanofi will look after commercialisation activities and record revenues.

The European Union, the US, China, and Japan are some of the countries where Beyfortus has already been approved for use.

–IANS

rvt/svn/vd

Go to Source

Disclaimer

The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.

Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.

Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

For any legal details or query please visit original source link given with news or click on Go to Source.

Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.

If you are not willing to accept this disclaimer then we recommend reading news post in its original language.

RELATED ARTICLES
- Advertisment -

Most Popular